NANO Nuclear Energy Inc.

NASDAQ•NNE

CEO: Mr. Jiang Yu

セクター: Industrials

業種: Industrial - Machinery

上場日: 2000-01-05

NANO Nuclear Energy Inc. operates as a microreactor technology company. The company is developing ZEUS, a solid-core battery reactor, and ODIN, a low-pressure coolant reactor. It is also developing a high-assay low-enriched uranium fabrication facility to supply fuel to the nuclear reactor industry and fuel transportation and nuclear consultation businesses. The company was founded in 2021 and is based in New York, New York.

連絡先情報

10 Times Square, 30th Floor, New York, NY, 10018, United States

212-634-9206

nanonuclearenergy.com

時価総額

$978.86M

PER (TTM)

-27.0

22.2

配当利回り

52週高値

$60.87

52週安値

$17.26

52週レンジ

14%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

4年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2022-2025

財務ダッシュボード

Q1 2026 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.13+0.00%

直近4四半期の推移

フリーCF

-$3.99B+0.00%

直近4四半期の推移

2026 Q1 決算ハイライト

主なハイライト

Strong Financing Inflow Net cash from financing $381.33M USD; October 2025 private placement raised $400.00M gross USD.

R&D Spending Accelerates R&D expense $5.40M USD for three months, up 497% versus prior period's $0.90M USD spend.

Cash Position Strengthened Cash equivalents reached $577.53M USD December 31, 2025; working capital $576.43M USD.

Reactor Licensing Progress NRC approved Fuel Qualification Methodology Topical Report; targeting construction permit submission first half 2026.

リスク要因

Future Funding Uncertainty Future capital needs require equity/debt financing; inability to raise funds could materially affect operations failure.

Regulatory Timeline Risks KRONOS reactor licensing timeline uncertain; NRC review timing outside management control, potentially delaying commercialization.

Operating Loss Widening Net loss $6.52M USD for quarter, nearly doubling prior period's $3.11M USD loss; cash used in operations $3.99M USD.

SEC Investigation Ongoing Received subpoena regarding two service providers; cannot predict outcome of SEC investigation initiated April 2025.

見通し

KRONOS Commercialization Target Aiming for NRC construction permit submission first half 2026; initial operation projected between 2030 and 2031.

Illinois Facility Investment Plan investment over $12M USD in Illinois facility for manufacturing and R&D; expecting $6.8M USD in incentives.

Consulting Revenue Near Term Generating small consulting revenue in 2025; formal launch dependent on acquiring existing revenue-generating businesses.

ODINT Reactor Sale Considered Signed Letter of Intent for proposed sale of ODINT microreactor design to monetize investment and focus resources.

同業比較

売上高 (TTM)

ZIM

$7.59B

+1.6%

$2.52B

-19.2%

ENOV

$2.25B

+6.7%

粗利益率 (最新四半期)

ENOV

60.7%

+3.2pp

EPAC

49.6%

-1.8pp

SXI

39.7%

+2.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ZIM	$3.35B	3.3	25.2%	52.1%
SXI	$3.04B	56.1	7.7%	40.1%
ATS	$2.96B	213.2	1.1%	35.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月13日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし